Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Artificial Intelligence Neurology

AstraZeneca Signs AI Deal To Pursue Novel Parkinson's Drugs

Executive Summary

AstraZeneca is the most recent big pharma to team up with an artificial intelligence business – following in the footsteps of Takeda, Johnson & Johnson, Sanofi and GlaxoSmithKline – having signed a drug discovery deal with Boston-based BERG.

You may also be interested in...



What's Next For Artificial Intelligence In The Clinic?

Numerate CEO Guido Lanza talks to Scrip about how artificial Intelligence, or AI, has been quietly used by some drug developers for the last decade, but its use is now rocketing. Also, what is next for AI in pharma?

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

Table

View full table

Topics

Related Companies

Tags:
Deals Artificial Intelligence Neurology
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC099370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By